Immunitybio Inc
$ 7.70
6.21%
17 Apr - close price
- Market Cap 7,951,929,000 USD
- Current Price $ 7.70
- High / Low $ 7.90 / 7.26
- Stock P/E N/A
- Book Value -0.50
- EPS -0.38
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.36 %
- ROE N/A %
- 52 Week High 12.43
- 52 Week Low 1.83
About
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.
Analyst Target Price
$14.80
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-03 | 2025-11-05 | 2025-08-05 | 2025-05-07 | 2025-03-17 | 2024-11-06 | 2024-08-06 | 2024-05-09 | 2024-03-19 | 2023-11-09 | 2023-08-08 | 2023-05-11 |
| Reported EPS | -0.06 | -0.07 | -0.1 | -0.15 | -0.08 | -0.1232 | -0.2 | -0.2 | -0.35 | -0.19 | -0.32 | -0.27 |
| Estimated EPS | -0.1106 | -0.11 | -0.11 | -0.16 | -0.13 | -0.18 | -0.17 | -0.16 | -0.18 | -0.25 | -0.23 | -0.27 |
| Surprise | 0.0506 | 0.04 | 0.01 | 0.01 | 0.05 | 0.0568 | -0.03 | -0.04 | -0.17 | 0.06 | -0.09 | 0 |
| Surprise Percentage | 45.7505% | 36.3636% | 9.0909% | 6.25% | 38.4615% | 31.5556% | -17.6471% | -25% | -94.4444% | 24% | -39.1304% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.08 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IBRX
2026-04-19 15:39:47
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) and certain officers, alleging federal securities law violations. The lawsuit claims that ImmunityBio's CEO, Soon-Shion, materially overstated the capabilities of Anktiva, and that the company's statements about its business, operations, and prospects were false and misleading during the period of January 19, 2026, to March 24, 2026. Investors who purchased ImmunityBio securities during this period are encouraged to join the case and have until May 26, 2026, to request to be appointed as lead plaintiff.
2026-04-19 15:39:47
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) and certain officers, alleging federal securities law violations. The lawsuit claims that the company made materially false and misleading statements regarding Anktiva’s capabilities during the Class Period, January 19, 2026, to March 24, 2026. Investors who suffered losses are encouraged to join the case, with a lead plaintiff deadline of May 26, 2026.
2026-04-18 18:39:47
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of investors who purchased securities between January 19, 2026, and March 24, 2026. The lawsuit follows an FDA warning letter stating that ImmunityBio's promotional materials for Anktiva were false or misleading, leading to a 21% stock drop. Investors have until May 26, 2026, to move the court to serve as a lead plaintiff.
2026-04-18 16:39:15
Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against ImmunityBio, Inc. (IBRX) on behalf of investors who purchased securities between January 19, 2026, and March 24, 2026. The lawsuit alleges that ImmunityBio made materially false statements regarding its lead biologic product, Anktiva, claiming it was a cancer vaccine and overstating its capabilities. The lawsuit stems from an FDA Warning Letter citing inaccurate claims made by ImmunityBio's Executive Chairman, causing the stock to drop significantly.
2026-04-18 15:10:14
Kessler Topaz Meltzer & Check, LLP has announced a securities fraud class action lawsuit against ImmunityBio, Inc. (IBRX) for investors who purchased securities between January 19, 2026, and March 24, 2026. The lawsuit alleges that ImmunityBio made materially false or misleading statements regarding its lead biologic product, Anktiva. The deadline for investors to seek lead plaintiff status is May 26, 2026.
2026-04-18 11:10:14
Kaplan Fox & Kilsheimer LLP has initiated a class action lawsuit against ImmunityBio, Inc. for alleged securities fraud during the Class Period of January 19, 2026, to March 24, 2026. This action follows the FDA issuing a warning letter to ImmunityBio for "false or misleading" advertising of Anktiva, leading to a significant stock price drop. Investors who suffered losses are encouraged to contact Kaplan Fox, with a deadline of May 26, 2026, to move for lead plaintiff status.
